Appendix H. Excluded Studies

Breast Cancer


124. Berstein LM, Iyevleva AG, Vasilyev D, Poroshina TE, Imyanitov EN. Genetic polymorphisms potentially
associated with response to metformin in postmenopausal diabetics suffering and not suffering with


outcome of interest.

127. Besic N, Satej N. Insulin glargine versus other types of basal insulin-clinical and tumor characteristics


130. Bhandari V, Boutros PC. Comparing continuous and discrete analyses of breast cancer survival

131. Bhargava R, Dabbs DJ. Oncotype DX test on unequivocally HER2-positive cases: potential for harm.

cancer: comparison with the expression of c erb B-2 oncoprotein. European Journal of Surgical Oncology.

polymorphism and BCL2 gene expression on the progression of breast cancer. Tumour Biology.


Exclude: Not intervention of interest.

136. Bianchini G, Pusztai L, Karn T, et al. Proliferation and estrogen signaling can distinguish patients at

value in estrogen receptor-positive and -negative cancers.[Erratum appears in J Clin Oncol. 2010 Nov


248. Chung C, Christianson M. Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: a systemic review of current development, evidence, and


468. Geradts J, Bean SM, Bentley RC, Barry WT. The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features. *Cancer Investigation*. 2010;28(9):969-977. Exclude: No outcome of interest.


486. Gluz O, Kreipe H, Christgen M, et al. Abstract P3-10-12: Pilot Phase of the Randomized PlanB Trial: Prospective Comparison of Molecular Classification, Oncotype DX(R) and Clinical-Pathological


576. Hanrahan EO, Valero V, Gonzalez-Angulo AM, Hortobagyi GN. Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literature. *Journal of Clinical Oncology*. 2006;24(13):2113-2122. Exclude: Date.


595. Health CAfDaTi. CADTH Rapid Response Reports. In: *Oncotype DX in Women and Men with ER-Positive, HER2-Negative Early Stage Breast Cancer who are Lymph Node Negative: A Review of Clinical Effectiveness and Guidelines.* Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; Copyright (c) 2014 Canadian Agency for Drugs and Technologies in Health.; 2014.


Gene expression profile testing for cancer tissue: draft report – appendices

European Society for Medical Oncology Congress, ESMO. 2016;27(no pagination). Exclude: Publication type-conference abstract.


**Prostate Cancer**


downregulation of zinc transporters.[Erratum appears in Appl Immunohistochem Mol Morphol. 2006
Publication type-not systematic review.
No outcome of interest.
provides risk stratification in prostate cancer: A discovery and validation cohort study. EBioMedicine.
2015;2(9):1133-1144. Exclude: Not intervention of interest.
localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-
intervention of interest.
170. Schoenborn JR, Nelson P, Fang M. Genomic profiling defines subtypes of prostate cancer with the
outcome of interest.
with early clinical failure and the impact of let-7 as prognostic marker in high-risk prostate cancer. PLoS
alterations highlights innate immune response suppression and cytoskeletal changes in prostate cancer.


**Colon Cancer**


245. Pan PY, Gu P, Li Q, Xu D, Weber K, Chen SH. Regulation of dendritic cell function by NK cells: mechanisms underlying the synergism in the combination therapy of IL-12 and 4-1BB activation. *Journal of Immunology.* 2004;172(8):4779-4789. Exclude: Not intervention of interest.


312. Uemura A, Takehara T, Miyagi T, et al. Natural killer cell is a major producer of interferon gamma that is critical for the IL-12-induced anti-tumor effect in mice. *Cancer Immunology, Immunotherapy*. 2010;59(3):453-463. Exclude: Not intervention of interest.


**Multiple Myeloma**


179. Usmani SZ, Rosenthal A, Sexton R, et al. Secondary myelodysplasia-associated metaphase cytogenetic abnormalities in newly diagnosed multiple myeloma treated on total therapies 2 & 3-


